Renaissance Technologies
RNAZ icon

Renaissance Technologies’s TransCode Therapeutics RNAZ Stock Holding History

Renaissance Technologies’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5
Closed -$31K – 4007
2023
Q4 		$31K Buy
+5
New +$56.2K ﹤0.01% 3529
2023
Q1 		– Hold
0
– -$9K – 4321
2022
Q4 		– Hold
0
– – – 4041
2022
Q3 		– Hold
0
– -$25K – 4348
2022
Q2 		– Hold
0
– – – 4100

Other funds holding RNAZ

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FPFS
First Personal Financial Services Charlotte, North Carolina $473M AUM 28.33% 1-Year Est. Return

Renaissance Technologies's RNAZ Position: Q1 2024 in Review

Renaissance Technologies sold out of TransCode Therapeutics (RNAZ) in Q1 2024, closing a stake of 5 shares — an estimated $31K sold.

Renaissance Technologies first reported a position in RNAZ in Q4 2023 and held it in 1 quarter. The position peaked at $31K in Q4 2023. 4 funds tracked by Wall St. Rank hold RNAZ as of Q1 2024.

  • Renaissance Technologies reported no remaining TransCode Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Renaissance Technologies sold 5 TransCode Therapeutics shares in Q1 2024, an estimated $31K.
  • Renaissance Technologies first reported a position in TransCode Therapeutics in Q4 2023 and held it in 1 quarter.
  • Renaissance Technologies's TransCode Therapeutics position peaked at $31K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.